Zobrazeno 1 - 10
of 31
pro vyhledávání: '"Victor J Weigman"'
Autor:
Jon S. Zawistowski, Isai Salas-Gonzalez, Tia A. Tate, Tatiana V. Morozova, Katherine Kennedy, Durga M. Arvapalli, Swetha D. Velivela, Jamie E. Remington, Josh Croteau, Kevin Taylor, Jeff G. Blackinton, Victor J. Weigman, Jeffrey R. Marks, Eun-Sil Shelley Hwang, Gary L. Harton, Jay A. West
Publikováno v:
Cancer Research. 83:5933-5933
The ResolveOME™ single-cell amplification solution unites whole-genome and full-length transcriptome information from the same cell, providing critical insight between these layers not possible when analyzed in isolation. We expand here upon the co
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::acb7d91a61bb75597bd216b55b3a9149
https://doi.org/10.1158/1538-7445.am2023-5933
https://doi.org/10.1158/1538-7445.am2023-5933
Autor:
Jan Budczies, David Fabrizio, H. Mellert, Mark Li, M. Butler, Phillip Stafford, K. Eyring, Diana Merino Vega, Mark Stewart, Dinesh Cyanam, Kristen Meier, Chen Zhao, Paul M. Williams, Justin Newberg, Warren Tom, Sarabjot Pabla, Ethan Sokol, A. Stenzinger, V.R. Gregersen, Vincent Funari, P. Beer, Roberto Salgado, Lisa M. McShane, G. Pestano, Jen-Hao Cheng, L.K. Bruce, Mingchao Xie, Laura M. Yee, J. Carl Barrett, Jeffrey M. Conroy, Laura Lasiter, R. Samara, Victor J. Weigman, George Green, Jonathan F. Baden, Tomas Vilimas, Jeff Allen, Matthew D. Hellmann, K.C. Valkenburg, Ahmet Zehir, A. J. Lazar, Elizabeth P. Garcia, Laura E. MacConaill, Laurel Keefer, Shu-Jen Chen, X.Z. Wang, Li Chen, A. Pallavajjalla, Yingdong Zhao, Q. Xie
Publikováno v:
Annals of Oncology. 32:1626-1636
Background Tumor mutational burden (TMB) measurements aid in identifying patients who are likely to benefit from immunotherapy; however, there is empirical variability across panel assays and factors contributing to this variability have not been com
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::170bd38401051eeae84d71008ef32716
https://doi.org/10.1016/j.annonc.2021.09.016
https://doi.org/10.1016/j.annonc.2021.09.016
Autor:
Jon S. Zawistowski, Isai Salas-González, Tatiana V. Morozova, Jeff G. Blackinton, Tia Tate, Durga Arvapalli, Swetha Velivela, Gary L. Harton, Jeffrey R. Marks, E. Shelley Hwang, Victor J. Weigman, Jay A.A. West
Discovering genomic variation in the absence of information about transcriptional consequence of that variation or, conversely, a transcriptional signature without understanding underlying genomic contributions, hinders understanding of molecular mec
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f02b57120e0460e9c1b8272715c52b35
https://doi.org/10.1101/2022.04.29.489440
https://doi.org/10.1101/2022.04.29.489440
Autor:
Vikas Gupta, Arnaud Papin, Warren Tom, Mingchao Xie, Elizabeth P. Garcia, Christopher D. Gocke, Lauryn Keeler, Jen-Hao Cheng, Laura E. MacConaill, Brett Kennedy, Lisa Haley, David Fabrizio, Ethan Sokol, Jeff Allen, Sean T. Glenn, Laurel Keefer, Jeffrey M. Conroy, J. Carl Barrett, Shu-Jen Chen, Matthew D. Hellmann, Laura M. Yee, Lisa M. McShane, Alexander J. Lazar, Diana M. Merino, Chen Zhao, Rajesh Patidar, Victor J. Weigman, Vincent Funari, Naiyer A. Rizvi, Kristen Meier, John F. Thompson, Kenneth R. Eyring, Tomas Vilimas, Mark Stewart, Dinesh Cyanam, Phillip Stafford, P. Mickey Williams
Publikováno v:
Cancer Research. 80:5671-5671
Introduction: Tumor mutational burden (TMB) is the number of somatic mutations per megabase in a tumor's genome and has shown promise as a predictive biomarker of response to immune checkpoint inhibitors across several cancers. TMB is typically measu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::408a09e39be3af6212ba7b51fcd191c8
https://doi.org/10.1158/1538-7445.am2020-5671
https://doi.org/10.1158/1538-7445.am2020-5671
Autor:
Victor J. Weigman, Rajiv Raja, Tingting Jiang, Stephanie B. Hastings, Philip Brohawn, Gunjan Hariani, Chen Zhao, Patrick Hurban, Traci Pawlowski
Publikováno v:
Cancer Research. 79:1346-1346
Checkpoint inhibitor (CPI) therapy demonstrates a remarkable clinical benefit in many cancer types. However, the ability to successfully select patients who will benefit from CPIs is still limited. Tumor mutational burden (TMB), a measure of the numb
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::abc9d2fdfb4ca264a405a1a37196c444
https://doi.org/10.1158/1538-7445.am2019-1346
https://doi.org/10.1158/1538-7445.am2019-1346
Publikováno v:
Cancer Research. 78:LB-381
Immunotherapies are an emerging approach for cancer treatment that leverage the power of the immune system to attack cancer cells. By targeting immune check-point pathways such as PD-1, these treatments have been highly effective for some patients di
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::20c1f1abbf7d38d41c676ca295b46fb6
https://doi.org/10.1158/1538-7445.am2018-lb-381
https://doi.org/10.1158/1538-7445.am2018-lb-381
Publikováno v:
Cancer Research. 78:2250-2250
Tumor mutational burden (TMB) is defined as the number of somatic mutations per Mb of the genome and is used to represent accumulation of somatic mutations over the life of the tumor. Recent evidence has shown that high TMB scores are associated with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8a381e62d5e575b9bc8f03e723ead4ee
https://doi.org/10.1158/1538-7445.am2018-2250
https://doi.org/10.1158/1538-7445.am2018-2250
Publikováno v:
Cancer Research. 78:2296-2296
Genomic structural variation and associated RNA fusions are a common clinical feature known to be involved in the initiation and pathogenesis of cancer. This complex class of variants also has significant implications on therapeutic decisions and has
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::26719174ac34ea7ae65ff2e6f65f1f76
https://doi.org/10.1158/1538-7445.am2018-2296
https://doi.org/10.1158/1538-7445.am2018-2296
Publikováno v:
Cancer Research. 78:LB-380
In most standard cases, mutational burden is derived from samples where mutational calling is performed in tumor and matched normal specimens. While this is ideal to get a true sense of tumor-derived mutations, it creates limitations due to cost of e
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::99f5f1b3c7035d4536f603903d3069c5
https://doi.org/10.1158/1538-7445.am2018-lb-380
https://doi.org/10.1158/1538-7445.am2018-lb-380
Autor:
Richard Bourgon, Yinghui Guan, Garret Hampton, Shan Lu, Yibing Yan, David Wang, Hartmut Koeppen, Weiru Wang, Yulei Wang, Mark R. Lackner, Lisa Ryner, Lukas C. Amler, Victor J. Weigman, Rajesh Patel
Publikováno v:
Clinical Cancer Research. 20:2080-2091
Purpose: Tailoring cancer treatment to tumor molecular characteristics promises to make personalized medicine a reality. However, reliable genetic profiling of archived clinical specimens has been hindered by limited sensitivity and high false-positi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::db36309f2dfb6cebb97bfcbac22cf7ee
https://doi.org/10.1158/1078-0432.ccr-13-3114
https://doi.org/10.1158/1078-0432.ccr-13-3114